Blue Ash Therapeutics, LLC was formed in December 2008 in Cincinnati to bring a promising cardiovascular drug – azimilide - to market. Azimilide is an oral once-daily cardiac antiarrhythmic (AA) drug for use in patients whose life-threatening arrhythmias require an implantable cardioverter-defibrillator (ICD) as a therapy of last resort.

Blue Ash Therapeutics seeks to commercialize not only azimilide, but to grow into a Cincinnati-based company specializing in acute-care cardiovascular therapies.